Shunsuke Teraoka

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto et al. · Journal of Thoracic Oncology · 2017 · 377 citations · Full text

Medicine, Immunology, Oncology +14

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 158 citations

Medicine, Oncology, Pharmacotherapy +8

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu et al. · International Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Metastasis +12

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14